Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

Atrial fibrillation (AF) has been reported in up to 16% of patients taking ibrutinib. Data regarding the management of AF in this patient population are limited, and stroke prevention poses a challenge because of increased risk of bleeding with ibrutinib treatment. Our study sought to describe the i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Wiczer, Tracy E., Levine, Lauren B., Brumbaugh, Jessica, Coggins, Jessica, Zhao, Qiuhong, Ruppert, Amy S., Rogers, Kerry, McCoy, Anli, Mousa, Luay, Guha, Avirup, Heerema, Nyla A., Maddocks, Kami, Christian, Beth, Andritsos, Leslie A., Jaglowski, Samantha, Devine, Steven, Baiocchi, Robert, Woyach, Jennifer, Jones, Jeffrey, Grever, Michael, Blum, Kristie A., Byrd, John C., Awan, Farrukh T.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2017
Teme:
Lymphoid Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728342/
https://ncbi.nlm.nih.gov/pubmed/29296820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017009720
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items